Wickham Labs to Exhibit at Medtec Ireland 2017

Sep 14, 2017

Wickham Laboratories Ltd is pleased to announce that we will be on stand 305 at the upcoming Medtec Ireland, held on 4-5 October 2017 at the Radisson Blu Hotel in Galway, Ireland. Medtec Ireland is a dedicated exhibition providing a platform for suppliers and industry professionals to meet, trade and learn. The 2017 event will host over 900 medical technology international professionals, with presentations covering the main issues for the medtech industry. We look forward to joining medical device developers and manufacturers in Galway next month and welcome you to stop by stand 305 to talk about what we can ...

Read More

Oxford Genetics Supports Significant Growth with New U.S. Office

Sep 12, 2017

Company to extend its presence into the U.S. as a key cell and gene therapy market  12 September, 2017, Oxford – Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has announced that it has opened its first U.S. office located at the NGIN workplace near Kendall Square in the Cambridge district of Boston. By expanding into the U.S. market, the company is well positioned to respond to its existing customers’ needs, while also leveraging the very attractive sector and growing market. This is the company’s first office outside of the U.K., and will support ...

Read More

Recipharm and CTC launch integrated first in human service

Sep 12, 2017

Contract development and manufacturing organisation (CDMO) Recipharm and contract research organisation (CRO) Clinical Trial Consultants (CTC) have partnered to launch a new service that delivers a clear, streamlined pathway to first in human milestones. Recipharm Pathway to Clinic™ takes projects from early phase formulation development through to clinical trial implementation with patients, helping companies, ranging from small, virtual firms to big pharma, quickly generate data and build value in their compound. From its development sites in Solna and Uppsala, Sweden, Recipharm performs formulation development, GMP clinical supply manufacture and bioanalysis on behalf of its clients. This will be closely integrated ...

Read More

Combination Data for Lenvatinib and Pembrolizumab Demonstrate Notable Response Rates for Patients with Advanced Renal Cell Carcinoma

Sep 12, 2017

Updated results of advanced RCC cohort from Study 111 support continued investigation of first-line use of the combination in ongoing Phase III study (CLEAR) Phase Ib/II results to be presented in an oral proffered paper session on Saturday, 9 September at 9:15 a.m. CEST at European Society for Medical Oncology (ESMO) 2017 Congress  Eisai today announced interim results from the advanced renal cell carcinoma (RCC) cohort of Study 111 of Kisplyx® (lenvatinib) in combination with the Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside of the United States and Canada) anti-PD-1 therapy, pembrolizumab (KEYTRUDA®). The results demonstrate that the ...

Read More

Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Phase 3 Trial in Uncontrolled Persistent Asthma

Sep 12, 2017

– Investigational dupilumab reduced severe asthma attacks and improved lung function –     Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints. Dupilumab, when added to standard therapies, reduced severe asthma attacks (exacerbations) and improved lung function. At 52 weeks, in the 300 mg dose group, dupilumab reduced severe asthma attacks by 46 percent in the overall population, 60 percent in patients with 150 eosinophilic cells/microliter or greater, and 67 percent in patients with 300 eosinophilic cells/microliter or greater (p ...

Read More